Anti-HIV therapy with AZT prodrugs: AZT phosphonate derivatives, current state and prospects

Bibliography

• De Clercq E. New development in anti-HIV chemotherapy. Biochim Biophys Acta 2002;1587:258-75
   PubMed Web of Science ®Google Scholar
• Groschel B, Cinatl JH, Cinatl J Jr. Viral and cellular factors for resistance against antiretroviral agents. Intervirology 1997;40:400-7
   PubMed Web of Science ®Google Scholar
• Antonelli G, Turriziani O, Verri A, Long-term exposure to zidovudine affects in vitro and in vivo the efficiency of thymidine kinase. AIDS Res Hum Retrovir 1996;12:223-8
   PubMed Web of Science ®Google Scholar
• Chariot P, Drogou I, De Lacroix-Szmania I, Zidovudine-induced mitochondrial disorder with massive liver steanosis, myopathy, lactic acidosis, and mitochondial DNA depletion. J Hepatol 1999;30:156-60
   PubMed Web of Science ®Google Scholar
• Gelmon K, Montaner JSG, Fanning M, Nature, time course and dose dependence of zidovudine-related side effects: results from the Multicenter Canadian Azidothymidine Trial. AIDS 1989;3(9):555-61
   PubMed Web of Science ®Google Scholar
• Pan-Zhou X-R, Cui L, Zhou X-J, Differential effects of antiretroviral nucleoside analogs on mitochondrial function in HepG2 cells. Antimicrob Agents Chemother 2000;44:496-503
   PubMed Web of Science ®Google Scholar
• Chiao SK, Romero DL, Johnson DE. Current HIV therapeutics: mechanistic and chemical determinants of toxicity. Curr Opin Drug Discov Devel 2009;12(1):53-60
   PubMed Web of Science ®Google Scholar
• Kellam P, Boucher CA, Larder BA. Fifth mutations in HIV reverse transcriptase contributes to the development of high level resistance to zidovudine. Proc Natl Acad Sci USA 1992;89:1934-8
   PubMed Web of Science ®Google Scholar
• Ren J, Esnouf RM, Hopkins AL, 3′-Azido-3′-deoxythymidine drug resistance mutations in HIV-1 reverse transcriptase can induce long range conformational changes. Proc Natl Acad Sci USA 1998;95:9518-23
   PubMed Web of Science ®Google Scholar
• Stańczak A, Ferra A. Prodrugs and soft drugs. Pharmacol Rep 2006;58(5):599-613
   PubMed Web of Science ®Google Scholar
• Beaumont K, Webster R, Gardner I, Dack K. Design of ester prodrugs to enhance oral absorption of poorly permeable compounds: challenges to the discovery scientist. Curr Drug Metab 2003;4(6):461-85
   PubMed Web of Science ®Google Scholar
• Calogeropoulou T, Detsi A, Lekkas E, Koufaki M. Strategies in the design of prodrugs of anti-HIV agents. Curr Top Med Chem 2003;3(13):1467-95
   PubMed Web of Science ®Google Scholar
• Tarusova NB, Khorlin AA, Kraevskii AA, Inhibition of reproduction of HIV in cell culture by 5′-phosphonates of 3′-azido-2′, 3′-dideoxynucleosides. Mol Biol 1989;23(6):1716-24
   Google Scholar
• Tarussova NB, Krayevsky AA, Korneyeva MN, Georgii A. New phosphonate derivatives of nucleoside analogues as anti – HIV agents. Collection Chem Commun 1990;44(2):133-6
   Google Scholar
• Karamov EV, Lukashov VV, Tarussova NB, Inhibition of human immunodeficiency virus in cell cultures with 5′-phosphites of 3′-azido-2′,3′-dideoxynucleosides. Mol Biol 1990;24(6):1695-701
   Google Scholar
• Krayevsky AA, Tarussova NB, Zhu Q-Y, 5′-Hydrogenphosphonates and 5′-methylphosphonates of sugar modified pyrimidine nucleosides as potential anti-HIV-1 agents. Nucleos Nucleot 1992;11(2-4):177-96
   Google Scholar
• Tarussova NB, Kukhanova MK, Kraevsky AA, Inhibition of HIV production by 5′-hydrogenphosphonates of 3′-azido-2′, 3′-dideoxynucleosides. Nucleos Nucleot 1991;10(1-3):351-4
   Google Scholar
• Kukhanova MK, Kuznetsova EV, Arzumanov AA, Krayevsky AA. Phosphate-modified nucleotides: conversions in human serum. Nucleos Nucleot 1995;14(3-5):997-1000
   Google Scholar
• Machado J, Salomon H, Oliveira M, Antiviral activity and resistance profile of phosphazid – a novel prodrug of AZT. Nucleos Nucleot 1999;18(4-5):901-6
   PubMedGoogle Scholar
• Khorlin AA, Tarusova NB, Dyatkina NB, 5′-Phosphonates of 2′,3′-dideoxynucleosides. RF1548182; 1992, US5043437; 1991, EP0354246; 1994, Japan 0354246 B1; 1995, Korean 106957; 1996
   Google Scholar
• Yurin O, Kravtchenko A, Serebrovskaya L, The phase 1 of the clinical trial of ‘Phosphazid’, the new reverse transcriptase inhibitor [abstract]. 4th International Congress on drug therapy in HIV-infection; Glasgow, UK; 1998;12(4):240
   Google Scholar
• Yurin OU, Krayevsky AA, Afonina LYu, Phosphazid – a new antiretroviral drug. Epidemiol Infect Dis (Russian) 2001;1:43-5
   Google Scholar
• Gosselin G, Perigaud C, Lefebvre I, 5′-Hydrogenphosphonates of anti-HIV nucleoside analogues revisited: controversial mode of action. Antiviral Res 1993;22(2-3):143-53
   PubMed Web of Science ®Google Scholar
• McGuigan C, Bellevergue P, Jones BCNM, Alkyl hydrogen phosphonate derivatives of the anti-HIV agent AZT may be less toxic than the parental nucleoside analogue. Antivir Chem Chemother 1994;5:271-7
   Web of Science ®Google Scholar
• Galegov G. Nikavir (Phosphazide), an antiretroviral agent: anti-HIV activity, toxicology, pharmacokinetics and some perspectives of clinical use. Antibiot Chemother (Russian) 2004;49(7):3-8
   Google Scholar
• Skoblov Yu, Karpenko I, Shirokova E, Intracellular metabolism and pharmacokinetics of 5′-hydrogenphosphonate of 3′-azido-2′,3′-dideoxythymidine, a prodrug of 3′-azido-2′, 3′-dideoxythymidine. Antiviral Res 2004;63(2):107-13
   PubMed Web of Science ®Google Scholar
• Kukhanova MK, Shirokova EA. 5′-O-modified nucleoside analogues as prodrugs of anti-HIV agents. Front Nucleic Acids 2005;339-41
   Google Scholar
• Yurin O, Kravtchenko A, Afonina L, Treatment of the patients with intolerance to AZT by phosphazid [abstract]. 5 International Congress on drug therapy in HIV-infection; Glasgow, UK; 2001;14(Suppl 4). p. 13
   Google Scholar
• Kravtchenko AV. Application of Nikavir in HEART. Med Tribune 2004;2:90-2, 166-72 (Rus)
   Google Scholar
• Yurin O, Kravtchenko A, Kanestri V, First experience of the application of (phosphazide) the new nucleotide analogue in HAART [abstract]. 13th International AIDS Conference; Durban, South Africa; 2000; Abstract book V.1:TuPeB3205
   Google Scholar
• Kravtchenko AV, Salamov GG, Bogoslovskaya EV, Three-component combined antiretroviral therapy using HIV reverse transcriptase inhibitors. Epidemiol Infect Dis 2001;4:32-5 (Rus)
   Google Scholar
• Kravtchenko AV, Sitdykova YuP, Serebrovskaya LV, Combined antiretroviral therapy of HIV infected patients using ‘reinforced’ HIV protease inhibitors. Infect Dis 2003;1(1):14-19 (Rus)
   Google Scholar
• Pokrovskii VV, Yurin OG, Belyaeva VV, Clinical diagnostics and treatment of HIV infection (Recommendations for students, interns, residents and doctors of other specialities). Moscow: GOU VUNMTs, Ministry of Health of Russian Federation; 2001, (Rus)
   Google Scholar
• Detkova NV. Chemoprophylaxis of HIV transmission from mother to the child. Thesis of Doctor of medical sciences, Moscow; 2003, (Rus)
   Google Scholar
• Detkova NV, Sokolova EV, Bobkova MR, Nevirapin (Viramune), a drug for prevention of HIV transmission from mother to child. Epidemiol Infect Dis (Russian) 2003;6:55-7
   Google Scholar
• Ivanova EI, Vorobyeva NN. Nicavir in perinatal chemoprophylaxis. Oncology-XXI century. IV(XIII) International conference, Vietnam; 2009. p. 88-91
   Google Scholar
• Mirzoev T. Chemoprophylaxis of vertical HIV transmission from mother to child. Doctor In Charge 2005;10:20-6 (Rus)
   Google Scholar
• Yurin O, Kravtchenko A, Afonina L, Treatment of the patients with intolerance to AZT by phosphazid [abstract]. 8th International Congress on drug therapy in HIV-infection, Glasgow, UK; 2006. p. 395
   Google Scholar
• Ivanova ES, Vorobyova NN, Krasnoperova NN, Prevention of HIV infecting of medical personnel. Materials of scientific session of Vagner State Medical Academy. Perm' 2007EA:110-12
   Google Scholar
• Orders of Ministry of Health of Russian Federation No 606 of 19.12.03 and No 375 of 30.05.05. Approval of Instruction on prophylaxis of transmission of HIV infection from mother to child and an application form of informed consent on HIV chemoprophylaxis (Rus)
   Google Scholar
• Kravtchenko AV, Salamov GG, Serebrovskaya LV, The first experience of HAART with phosphazide + didanosine + nevirapine in HIV-infected patients in Russia [abstract 3]. 5th International Conference on Drug Therapy, Glasgow, Scotland; 2000
   Google Scholar
• Sitdykova YR, Serebrovskaya LV, Kravchenko AV. Immune reconstitution on treatment of HIV-infected patients with phosphazide, didanosine and saquinavir/ritonavir once daily in Russia [abstract 2.7/1]. 9th EACS Warsaw, Poland; 2003
   Google Scholar
• Pokrovsky AG, Pronayeva TR, Fedyuk NV, Anti-HIV activity of novel phosphonate derivatives of Azt, d4T, and ddA. Nucleosides Nucleotides Nucleic Acids 2001;20(4-7):767-9
   PubMed Web of Science ®Google Scholar
• Khandazhinskaya AL, Shirokova EA, Karpenko IL, P-(alkyl)-nucleoside 5′-hydrogenphosphonates as depot forms of antiviral nucleotide analogues. Nucleosides Nucleotides Nucleic Acids 2000;19:1795-804
   PubMed Web of Science ®Google Scholar
• Jin Y, Xing L, Tian Y, Self-assembled drug delivery systems. Part 4. In vitro/in vivo studies of the self-assemblies of cholesteryl-phosphonyl zidovudine. Int J Pharm 2009;381(1):40-8
   PubMedGoogle Scholar
• Shirokova EA, Jasko MV, Khandazhinskaya AL, Uncharged AZT and D4T derivatives of phosphonoformic and phosphonoacetic acids as anti-HIV pronucleosides. J Med Chem 2004;47(14):3606-14
   PubMed Web of Science ®Google Scholar
• Shirokova EA, Jasko MV, Khandazhinskaya AL, New Lipophilic Derivatives of AZT and D4T 5′-Phosphonates. Nucleosides Nucleotides Nucleic Acids 2003;22:981-5
   PubMed Web of Science ®Google Scholar
• Shirokova EA, Ias'ko MV, Khandazhinskaia AL, New phosphonoformic acid derivatives of 3′-azido-3′-deoxythymidine. Bioorg Khim 2004;30(3):273-80 (Rus)
   PubMedGoogle Scholar
• Szymanska A, Szymczak M, Boryski J, Aryl nucleoside H-phosphonates. Part 15: synthesis, properties and, anti-HIV activity of aryl nucleoside 5′-alpha-hydroxyphosphonates. Bioorg Med Chem 2005;14(6):1924-34
   PubMed Web of Science ®Google Scholar
• Puech F, Gosselin G, Balzarini J, Synthesis and biological evaluation of dinucleoside methylphosphonates of 3′-azido-3′-deoxythymidine and 2′,3′-dideoxycytidine. Antiviral Res 1990;14(1):11-23
   PubMed Web of Science ®Google Scholar
• Meier C, Aubertin A-M, De Monte M, Synthesis and antiviral evaluation of sate-foscarnet prodrugs and new foscarnet-AZT conjugates. Antivir Chem Chemother, 1998;9(1):41-52
   PubMed Web of Science ®Google Scholar
• Meier C, Habel L, Laux W, Homo dinucleoside-alpha-hydroxyphosphonate diesters as prodrugs of the antiviral nucleoside analogues 2′,3′-dideoxythymidine and 3′-azido-2′,3′-dideoxythymidine. Nucleosides Nucleotides 1995;14(3-5):759-62
   Google Scholar
• Balzarini J, Herdewijn P, Pauwels R, Alpha, beta and beta, gamma-methylene 5′-phosphonate derivatives of 3′-azido-2′, 3′-dideoxythymidine-5′-triphosphate. Biochem Pharmacol 1988;37(12):2395-403
   PubMed Web of Science ®Google Scholar
• Jie L, Van Aerschot A, Balzarini J, Synthesis and anti-hiv evaluation of some 5′-o-phosphonomethyl-2′, 3′-dideoxynucleosides [abstract 22]. Antiviral Res 1990;0(Suppl 1):51
   Google Scholar
• Jie L, Van Aerschot A, Balzarini J, 5′-O-Phosphonomethyl-2′, 3′-dideoxynucleosides: synthesis and anti-HIV activity. J Med Chem 1990;33(9):2481-7
   PubMed Web of Science ®Google Scholar
• Freeman GA, Rideout JL, Miller WH, Reardon JE. 3′-Azido-3′, 5′-dideoxythymidine-5′-methylphosphonic acid diphosphates synthesis and HIV-1 reverse transcriptase inhibition. J Med Chem 1992;35(17):3192-6
   PubMed Web of Science ®Google Scholar
• Mackman RL, Zhang L, Prasad V, Synthesis and anti-HIV activity of cyclic pyrimidine phosphonomethoxy nucleosides and their prodrugs: a comparison of phosphonates and corresponding nucleosides. Nucleosides Nucleotides Nucleic Acids 2007;26(6-7):573-7
   PubMed Web of Science ®Google Scholar
• Mackman RL, Zhang L, Prasad V, Synthesis, anti-HIV activity, and resistance profile of thymidine phosphonomethoxy nucleosides and their bis-isopropyloxymethylcarbonyl (bisPOC) prodrugs. Bioorg Med Chem 2007;15(16):5519-28
   PubMed Web of Science ®Google Scholar
• Krayevsky A, Tarussova N, Zhu Q, New 5′-phosphonates of sugar-modified nucleosides as inhibitors of HIV production (translation). Molekulyarnaya Biologiya 1992;26(3):624-34
   Google Scholar
• Mamaeva OA, Plyasunova OA, Pokrovskii AG, Anti-HIV activity of azidothymidine and fluorothymidine 5′-phosphonates. Molekulyarnaya Biologiya 1994;28(1):90-3
   Web of Science ®Google Scholar
• Dyatkina N, Arzumanov A, Krayevsky A, Synthesis and antiviral activity of some fluorinated nucleotide derivatives. Nucleosides Nucleotides 1994;13(1-3):325-37
   Google Scholar
• Egron D, Arzumanov AA, Dyatkina NB, Synthesis, anti-HIV activity, and stability studies of 5[prime prime or minute]-phosphorofluoridate derivatives of AZT. Bioorg Chem 2001;29(6):333-44
   PubMed Web of Science ®Google Scholar
• Egron D, Arzumanov AA, Dyatkina NB, Synthesis, anti-HIV activity and stability studies of 3′-azido-2′, 3′-dideoxythymidine 5′-fluorophosphate. Nucleosides Nucleotides 1999;18(4-5):983-4
   PubMedGoogle Scholar
• Jasko M, Shipitsyn A, Khandazhinskaya A, New derivatives of alkyl- and aminocarbonylphosphonic acids containing 3′-azido-3′-deoxythymidine. Russ J Bioorgan Chem 2006;32(6):542-6
   Web of Science ®Google Scholar
• Rosowsky A, Fu HN, Pai N, Synthesis and in vitro activity of long-chain 5′-o-[(alkoxycarbonyl)phosphinyl]-3′-azido-3′-deoxythymidines against wild-type and azt- and foscarnet-resistant strains of HIV-1. J Med Chem 1997;40(16):2482-90
   PubMed Web of Science ®Google Scholar
• Kong XB, Zhu QY, Ruprecht RM, Synergistic inhibition of Human Immunodeficiency Virus type 1 replication in vitro by two-drug and three-drug combinations of 3′-azido-3′-deoxythymidine, phosphonoformate, and 2′, 3′-dideoxythymidine. Antimicrob Agents Chemother 1991;35(10):2003-11
   PubMed Web of Science ®Google Scholar
• Hammond JL, Koontz DL, Bazmi HZ, Alkylglycerol prodrugs of phosphonoformate are potent in vitro inhibitors of nucleoside-resistant Human Immunodeficiency Virus type 1 and select for resistance mutations that suppress zidovudine resistance. Antimicrob Agents Chemother 2001;45(6):1621-8
   PubMed Web of Science ®Google Scholar
• Kukhanova MK, Khandazhinskaya AL, Yasko MV, Modified azidothymidine 5′-phosphonate for potential antiviral preparations. EP1829885A1, WO2006/062434; 2006
   Google Scholar
• Khandazhinskaya AL, Yanvarev DV, Jasko MV, 5′-Aminocarbonyl phosphonates as new zidovudine depot forms: antiviral properties, intracellular transformations, and pharmacokinetic parameters. Drug Metab Dispos 2009;37(3):494-501
   PubMed Web of Science ®Google Scholar
• Kukhanova MK, Jasco MV, Shipitzyn AV, New depot forms of AZT and 3TC based on their phosphonate derivatives: anti-HIV activity and pharmacokinetic parameters. Nucleic Acids Symp Ser (Oxf) 2008;(52):597-8
   PubMedGoogle Scholar
• Drontle DP, Wagner CR. Designing a pronucleotide stratagem: lessons from amino acid phosphoramidates of anticancer and antiviral pyrimidines. Mini Rev Med Chem 2004;4(4):409-19
   PubMed Web of Science ®Google Scholar
• Chang SL, Griesgraber W, Southern PJ, Wagner CR. Amino acid phosphoramidate monoesters of 3′-azido-3′-deoxythymidine: relationship between antiviral potency and intracellular metabolism. J Med Chem 2001;44(2):223-1
   PubMed Web of Science ®Google Scholar
• Aquaro S, Wedgwood O, Yarnold C, Activities of masked 2′, 3′-dideoxynucleoside monophosphate derivatives against human immunodeficiency virus in resting macrophages. Antimicrob Agents Chemother 2000;44(1):173-7
   PubMed Web of Science ®Google Scholar
• Venkatachalam T, Samuel P, Qazi S, Uckun F. Effect of change in nucleoside structure on the activation and antiviral activity of phosphoramidate derivatives. Bioorg Med Chem 2005;13(18):5408-23
   PubMed Web of Science ®Google Scholar
• Kinchington D, Harvey JJ, O'Connor TJ, Comparison of antiviral effects of zidovudine phosphoramidate and phosphorodiamidate derivatives against HIV and ULV in vitro. Antivir Chem Chemother 1992;3(2):107-12
   Web of Science ®Google Scholar
• De Clercq E, Field HJ. Antiviral prodrugs – the development of successful prodrug strategies for antiviral chemotherapy. Br J Pharmacol 2006;147:1-11
   PubMed Web of Science ®Google Scholar
• Rosowsky A, Saha J, Fazely F, Inhibition of HIV-1 replication by phosphonoformate esters of 3′-azido-3′-deoxythymidine. Biochem Biophys Res Commun, 1990;172(1):288-94
   PubMed Web of Science ®Google Scholar
• Piantadosi C, Marasco JR CJ, Morris-Natschke SL, Synthesis and evaluation of novel ether lipid nucleoside conjugates for anti-HIV-1 activity. J Med Chem 1991;34(4):1408-14
   PubMed Web of Science ®Google Scholar